C
CutisPharma
Industry leader in bringing innovation to the pharmaceutical compounding market
About CutisPharma
Azurity Pharmaceuticals is a specialty pharmaceutical company focused on developing and providing high-quality, customized treatments for patients with unique medical needs. The company primarily serves pediatric and elderly patients who require tailored drug formulations that are easier to administer and more effective for their specific conditions. Operating in the pharmaceutical market, Azurity leverages its expertise to create both FDA-approved products and non-FDA-approved compounding kits. These products address unmet medical needs and offer alternatives to conventional dosage forms, ensuring better patient outcomes.
Azurity's business model revolves around the development, approval, and commercialization of these specialized treatments. The company generates revenue through the sale of its FDA-approved medications and compounding kits to healthcare providers, pharmacies, and hospitals. By focusing on niche markets with specific needs, Azurity is able to maintain a competitive edge and drive growth through innovation and quality.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 1998
- Headquarters
- Wilmington, United States
- Employees
- 916
- Open positions
- None listed
- Dealroom signal
- 53.6/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Client focus
- b2b
- Investment activity
- 1 company, latest Jun 2019
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Mar 2018 | $0 | — | Undisclosed | — |
| GROWTH EQUITY VC✓Equity / VC | Jan 2015 | $0 | — | Ampersand Capital Partners | — |
Growth signals
Latest recorded traffic for CutisPharma is 120 monthly website visits, down 57.1% over the last three months. CutisPharma's team grew 308.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Silvergate PharmaceuticalsGreenwood Village, United StatesAnd commercializes pediatric medications
→
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Ampersand Capital Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about CutisPharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See CutisPharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.